[go: up one dir, main page]

CN115160444A - Method for preparing hydrogel scaffolds and use of scaffolds obtained thereby - Google Patents

Method for preparing hydrogel scaffolds and use of scaffolds obtained thereby Download PDF

Info

Publication number
CN115160444A
CN115160444A CN202210998757.9A CN202210998757A CN115160444A CN 115160444 A CN115160444 A CN 115160444A CN 202210998757 A CN202210998757 A CN 202210998757A CN 115160444 A CN115160444 A CN 115160444A
Authority
CN
China
Prior art keywords
polypeptide
self
macrophages
hydrogel
scaffold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210998757.9A
Other languages
Chinese (zh)
Inventor
杨鹏翔
杨宇民
接晶
张鲁中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantong University
Original Assignee
Nantong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantong University filed Critical Nantong University
Priority to CN202210998757.9A priority Critical patent/CN115160444A/en
Publication of CN115160444A publication Critical patent/CN115160444A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3878Nerve tissue, brain, spinal cord, nerves, dura mater
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00Manufacture or treatment of nanostructures
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0645Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/12Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/32Materials or treatment for tissue regeneration for nerve reconstruction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2304Interleukin-4 (IL-4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/003D culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/50Proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/90Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

The invention relates to a method for preparing a hydrogel scaffold by utilizing self-assembled polypeptide and application of the scaffold obtained by the method, wherein the preparation method comprises the following steps: 1) Bonding the self-assembly peptide sequence with the nerve growth factor mimic peptide through a covalent bond to obtain a bonding functional polypeptide; 2) Separating and culturing macrophages, inducing the macrophages to be 'substitution activated' anti-inflammatory M2 macrophages, obtaining culture supernatant and filtering to obtain filtered cell culture supernatant; 3) And mixing the filtered cell culture supernatant with the bonded functional polypeptide to obtain a mixed solution, adjusting the concentration of the mixed solution, and performing self-assembly on the bonded functional polypeptide to form the hydrogel support. The invention adopts M2 macrophage condition culture supernatant to construct regeneration microenvironment, and combines with the polypeptide functional hydrogel bracket to realize better integral interaction, so as to prepare the hydrogel bracket capable of supplementing and regulating nerve regeneration, and the bracket can promote nerve cell regeneration behavior and provide a new choice for tissue engineering biomaterials.

Description

制备水凝胶支架的方法及由此得到的支架的用途Method for preparing hydrogel scaffolds and uses of scaffolds obtained therefrom

本申请是申请日为2021年7月27日、名称为“制备水凝胶支架的方法及由此得到的支架的用途”的申请号为202110849059.8的专利申请的分案申请。This application is a divisional application of the patent application with the application number of 202110849059.8 with the application date of July 27, 2021 and the title of "Method for preparing a hydrogel scaffold and use of the scaffold obtained therefrom".

技术领域technical field

本发明涉及组织工程技术领域,更具体而言,涉及一种利用自组装多肽制备水凝胶支架的方法以及由此得到的支架的用途。The present invention relates to the technical field of tissue engineering, and more particularly, to a method for preparing a hydrogel scaffold by using self-assembled polypeptides and the use of the scaffold obtained thereby.

背景技术Background technique

周围神经损伤的主要原因包括交通事故、机械创伤、自然灾害和手术意外。我国周围神经损伤病例每年新增约100万例,所照成难以恢复的残疾严重影响患者的生活质量和心理健康,为家庭和社会带来了沉重的经济负担。同时,本领域已知人工神经植入物的修复效果与自体神经相比还有差距,通过局部再生微环境调控提高植入物的功能,是能否实现临床应用的关键问题。The main causes of peripheral nerve injury include traffic accidents, mechanical trauma, natural disasters and surgical accidents. There are about 1 million new cases of peripheral nerve injury in my country every year, and the resulting disability that is difficult to recover seriously affects the quality of life and mental health of patients, and brings a heavy economic burden to the family and society. At the same time, it is known in the art that the repair effect of artificial nerve implants is still far from that of autologous nerves. Improving the function of implants through local regeneration microenvironment regulation is a key issue for clinical application.

组织工程技术的出现,为损伤神经修复提供了技术方式。组织工程包括三个要素:支架、种子细胞和信号因子。其中支架对于不仅对于再生组织起到物理连接和支持作用,而且在调控细胞再生环境发挥了重要作用。水凝胶的三维网络结构具有含水量高、适宜细胞生长的特点,通过交联生长因子模拟肽进一步提高了细胞生长环境,因此,如何成功地构建能够良好地模拟体内微环境的支架材料,对于损伤神经再生而言具有重要意义。The emergence of tissue engineering technology provides a technical way for the repair of damaged nerves. Tissue engineering consists of three elements: scaffolds, seed cells and signaling factors. Among them, scaffolds not only play an important role in physically connecting and supporting the regenerating tissue, but also in regulating the cell regeneration environment. The three-dimensional network structure of hydrogel has the characteristics of high water content and suitable for cell growth, and the cell growth environment is further improved by cross-linking growth factor mimetic peptides. Therefore, how to successfully construct a scaffold material that can well simulate the in vivo microenvironment is very important for It is important for the regeneration of damaged nerves.

巨噬细胞在体内分布极广,在调节炎症过程中发挥着巨大作用,具有高度可塑性,并在机体的发育及内环境的平衡中起到重要作用。巨噬细胞发生极化为M2表型后,极化后的巨噬细胞亚型可以细致调节及回应各种不同的刺激,分泌信号因子,抗慢性炎症,促进组织修复再生,对疾病组织器官的修复程度起着关键性的作用。关于M2巨噬细胞衍生的细胞外基质构建水凝胶支架的研究还未见报道,具有重要的研究价值。Macrophages are widely distributed in the body, play a huge role in regulating the inflammatory process, are highly plastic, and play an important role in the development of the body and the balance of the internal environment. After the macrophages are polarized to the M2 phenotype, the polarized macrophage subtypes can meticulously regulate and respond to various stimuli, secrete signaling factors, resist chronic inflammation, promote tissue repair and regeneration, and have a positive effect on diseased tissues and organs. The degree of repair plays a key role. The research on the construction of hydrogel scaffolds from M2 macrophage-derived extracellular matrix has not been reported yet, which has important research value.

发明内容SUMMARY OF THE INVENTION

本发明的一个方面是提供一种自组装多肽水凝胶支架制备方法,其中,所述方法包括:One aspect of the present invention is to provide a method for preparing a self-assembling polypeptide hydrogel scaffold, wherein the method includes:

(1)将自组装肽序列通过共价键键合神经生长因子模拟肽,得到键合功能多肽;(1) The self-assembled peptide sequence is covalently bonded to the nerve growth factor mimetic peptide to obtain a bonded functional polypeptide;

(2)分离并培养巨噬细胞,并诱导其为“替代性激活”的抗炎M2巨噬细胞,得到细胞培养上清液并进行过滤,得到经过滤的细胞培养上清液;(2) Isolating and culturing macrophages and inducing them to be "alternatively activated" anti-inflammatory M2 macrophages, obtaining cell culture supernatants and filtering them to obtain filtered cell culture supernatants;

(3)将所述经过滤的细胞培养上清液与所述键合功能多肽混合,得到混合液并调整所述混合液的浓度,所述键合功能多肽自组装形成水凝胶支架。(3) mixing the filtered cell culture supernatant with the binding functional polypeptide to obtain a mixed solution and adjusting the concentration of the mixed solution, and the binding functional polypeptide self-assembles to form a hydrogel scaffold.

优选地,神经生长因子模拟肽具有促进神经血管细胞再生的功能。Preferably, the nerve growth factor mimetic peptide has the function of promoting the regeneration of neurovascular cells.

优选地,自组装肽序列与神经生长因子模拟肽通过酰胺键或二硫键共价连接。Preferably, the self-assembling peptide sequence is covalently linked to the nerve growth factor mimetic peptide via an amide bond or a disulfide bond.

优选地,自组装肽序列与神经生长因子模拟肽摩尔比为(1~3):1。Preferably, the molar ratio of the self-assembling peptide sequence to the nerve growth factor mimetic peptide is (1~3):1.

优选地,巨噬细胞来自大鼠/小鼠腹腔或骨髓、或人外周血单个核淋巴细胞中的一种。Preferably, the macrophages are derived from one of rat/mouse peritoneal cavity or bone marrow, or human peripheral blood mononuclear lymphocytes.

优选地,步骤(2)所述培养在30℃~40℃、3%~10% CO2的条件下进行;进一步优选地,所述培养的过程包括:将所述巨噬细胞在培养基中生长至60%~80%的汇合度后,弃去培养液并利用PBS缓冲液进行洗涤,随后向洗涤后的培养物中加入新鲜培养基并继续培养36h以上、例如36~72h、优选40~50h;Preferably, the culturing in step (2) is carried out under the conditions of 30°C to 40°C and 3% to 10% CO 2 ; further preferably, the culturing process includes: culturing the macrophages in a medium After growing to 60%~80% confluence, discard the culture medium and wash with PBS buffer, then add fresh medium to the washed culture and continue to cultivate for more than 36h, such as 36~72h, preferably 40~ 50h;

优选地,采用孔径为0.2~0.45μm的过滤材料对所述细胞培养上清液进行过滤。Preferably, the cell culture supernatant is filtered using a filter material with a pore size of 0.2-0.45 μm.

优选地,M2巨噬细胞培养上清液的制备方法,其特征在于,所述细胞培养诱导物采用10ng/ml的 IL-4进行步骤(2)所述的诱导。Preferably, the method for preparing M2 macrophage culture supernatant is characterized in that the cell culture inducer adopts 10ng/ml IL-4 to conduct the induction in step (2).

优选地,多肽水凝胶支架具有纳米纤维结构。Preferably, the polypeptide hydrogel scaffold has a nanofibrous structure.

优选地,多肽水凝胶支架具有水凝胶的形态,调节后凝胶的pH为6.9~7.2,浓度为0.5wt%-4wt%。Preferably, the polypeptide hydrogel scaffold has the form of a hydrogel, the pH of the adjusted gel is 6.9-7.2, and the concentration is 0.5wt%-4wt%.

本发明的又一方面是提供上述的制备的水凝胶支架在体外培养神经雪旺细胞中的用途,其特征在于,所述支架促进神经雪旺细胞的生长和活性。Another aspect of the present invention is to provide the use of the prepared hydrogel scaffold for culturing neural Schwann cells in vitro, wherein the scaffold promotes the growth and activity of neural Schwann cells.

采用本发明的任一项所述的方法制备的多水凝胶支架在组织工程再生中的用途,其特征在于,所述支架促进损伤神经的再生。The use of the multi-hydrogel scaffold prepared by the method of any one of the present invention in tissue engineering regeneration is characterized in that the scaffold promotes regeneration of injured nerves.

本发明的有益效果是:The beneficial effects of the present invention are:

1. 通过化学修饰和自组装方法制备组份更加明确,功能性更强,安全性和效率更高的多肽水凝胶支架,具有的纳米结构更适宜损伤神经的修复,增强特异性神经细胞再生速度,改善临床治疗效果。1. By chemical modification and self-assembly methods, polypeptide hydrogel scaffolds with clearer components, stronger functions, higher safety and efficiency are prepared. The nanostructures are more suitable for the repair of damaged nerves and enhance the regeneration of specific nerve cells. speed and improve clinical outcomes.

2.合成含有不同神经生长因子模拟肽的序列,通过自组装技术制备水凝胶,进一步合成含有M2巨噬细胞条件培养条件的水凝胶支架,促进再生细胞协同治疗方向发展。2. Synthesize sequences containing different nerve growth factor mimetic peptides, prepare hydrogels by self-assembly technology, and further synthesize hydrogel scaffolds containing M2 macrophage conditioned culture conditions to promote the development of synergistic therapy of regenerative cells.

3.还可以选择不同多肽载体,不同神经生长因子模拟肽,针对不同神经细胞设计、制备个多肽水凝胶支架。3. Different polypeptide carriers and different nerve growth factor mimetic peptides can also be selected to design and prepare a polypeptide hydrogel scaffold for different nerve cells.

4.适宜的再生免疫环境仿生支架具有良好的神经细胞黏附和生长性能,适宜的组织相容性,纳米纤维接近于细胞外基质结构,采用本发明的方法制备的支架具有更好的再生微环境,为开发产品奠定基础。4. A suitable regenerative immune environment The bionic scaffold has good nerve cell adhesion and growth performance, suitable histocompatibility, nanofibers are close to the structure of extracellular matrix, and the scaffold prepared by the method of the present invention has a better regenerative microenvironment , laying the foundation for product development.

附图说明Description of drawings

图1为示出自组装肽序列通过共价键键合神经生长因子模拟肽的结构模式图。FIG. 1 is a schematic diagram showing the structure of a self-assembling peptide sequence bound to a nerve growth factor mimetic peptide by covalent bonds.

图2为示出诱导M2巨噬细胞显微镜下形态图。Figure 2 is a diagram showing the morphology of induced M2 macrophages under a microscope.

图3为示出M2巨噬细胞成熟度的流式细胞检测图。其中,示出了通过流式细胞术检测到CD206的表达百分比。FIG. 3 is a flow cytometric graph showing the maturity of M2 macrophages. Among them, the percent expression of CD206 detected by flow cytometry is shown.

图4为示出多肽水凝胶支架的透射电镜图。其中,示出了纳米纤维的结构。Figure 4 is a transmission electron microscope image showing a polypeptide hydrogel scaffold. Therein, the structure of the nanofibers is shown.

图5为示出多肽水凝胶支架的倾斜实验图。FIG. 5 is a diagram showing a tilt experiment of the polypeptide hydrogel scaffold.

图6为原代培养神经雪旺细胞显微镜下形态图。Figure 6 is a morphological diagram of primary cultured neural Schwann cells under microscope.

图7为示出经对照组培养的神经雪旺细胞和经多肽水凝胶支架培养的神经雪旺细胞的生长速度。其中,*代表P<0.05。FIG. 7 is a graph showing the growth rates of neural Schwann cells cultured in a control group and neural Schwann cells cultured on a polypeptide hydrogel scaffold. Wherein, * represents P<0.05.

具体实施方式Detailed ways

除非另有定义,否则本文使用的科技术语具有与本发明所属领域中的普通技术人员通常所理解的相同的含义。参见例如Singleton等,Dictionary of Microbiology andMolecular Biology 2nd ed.,J. Wiley & Sons (New York,NY 1994);Sambrook等,Molecular Cloning,A Laboratory Manual,Cold Springs Harbor Press(Cold SpringsHarbor,NY 1989)。Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. See, eg, Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY 1994); Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press (Cold Springs Harbor, NY 1989).

本领域技术人员将认识到可用于实施本发明的、与本文描述的方法和材料类似或等同的许多方法和材料。实际上,本发明并不限于本文所描述的方法和材料,而是可基于本发明的精神,进行各种常规调整或修改,并且调整或修改后的方案仍落入了本发明的保护范围之内。One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. In fact, the present invention is not limited to the methods and materials described herein, but various conventional adjustments or modifications can be made based on the spirit of the present invention, and the adjusted or modified solutions still fall within the protection scope of the present invention. Inside.

除非上下文明确地指出,否则本文所使用的术语“一个”和“一种”等涵盖了复数的对象。As used herein, the terms "a" and "an" and the like encompass plural referents unless the context clearly dictates otherwise.

在本文中,通过术语“约”修饰的对象涵盖了由于测量误差等引起的误差范围内的近似值。As used herein, what is modified by the term "about" encompasses approximations within error due to measurement error and the like.

在本文中,除非另有定义,所使用的术语“肿瘤微环境”是指肿瘤细胞的发生及生活的内环境,具有低氧、低PH以及高压的特点,这些特点使得肿瘤微环境中存在大量的生长因子、细胞趋化因子和各种蛋白水解酶所产生的免疫炎性反应,从而有利于肿瘤的增殖、侵袭、粘附、血管生成以及抗放射化疗,促使恶性肿瘤产生。In this paper, unless otherwise defined, the term "tumor microenvironment" is used to refer to the internal environment in which tumor cells develop and live, characterized by low oxygen, low pH, and high pressure, which make the tumor microenvironment contain a large number of The immune inflammatory response produced by growth factors, cell chemokines and various proteolytic enzymes is beneficial to tumor proliferation, invasion, adhesion, angiogenesis, and anti-radiotherapy chemotherapy, and promotes the occurrence of malignant tumors.

在一个实施方式中,本发明涉及一种自组装多肽水凝胶支架制备方法,其中,所述方法包括:In one embodiment, the present invention relates to a method for preparing a self-assembling polypeptide hydrogel scaffold, wherein the method comprises:

(1)将自组装肽序列通过共价键键合神经生长因子模拟肽,得到键合功能多肽;(1) The self-assembled peptide sequence is covalently bonded to the nerve growth factor mimetic peptide to obtain a bonded functional polypeptide;

(2)分离并培养巨噬细胞,并诱导其为“替代性激活”的抗炎M2巨噬细胞,得到细胞培养上清液并进行过滤,得到经过滤的细胞培养上清液;(2) Isolating and culturing macrophages and inducing them to be "alternatively activated" anti-inflammatory M2 macrophages, obtaining cell culture supernatants and filtering them to obtain filtered cell culture supernatants;

(3)将所述经过滤的细胞培养上清液与所述键合功能多肽混合,得到混合液并调整所述混合液的浓度,所述键合功能多肽自组装形成纳水凝胶支架。(3) mixing the filtered cell culture supernatant with the binding functional polypeptide to obtain a mixed solution and adjusting the concentration of the mixed solution, and the binding functional polypeptide self-assembles to form a nanohydrogel scaffold.

在本文中,所述自组装肽序列由谷氨酸,赖氨酸,丙氨酸,色氨酸,精氨酸等在水溶液中自组装形成长度为10~20个氨基酸的小分子多肽。作为优选的示例,所述小分子多肽水凝胶例如包括但不限于,RADARADARADARADA、KWKAKAKAKWK、EWEAEAEAE、FEFEFKFKK以及QQKFQFQFEQQ。以上氨基酸购于西格玛奥德里奇(上海)贸易有限公司。In this paper, the self-assembling peptide sequence is self-assembled from glutamic acid, lysine, alanine, tryptophan, arginine, etc. in an aqueous solution to form a small molecule polypeptide with a length of 10-20 amino acids. As a preferred example, the small molecule polypeptide hydrogels include, but are not limited to, RADARADARADARADA, KWKAKAKAKWK, EWEAEAEAE, FEFEFKFKK, and QQKFQFQFEQQ. The above amino acids were purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd.

在一个优选的实施方式中,所述神经生长因子模拟肽可为本领域已知的任何一种,例如,来自选自如下的一种或多种,神经生长因子(NGF)、脑源性神经营养因子(BDNF)、血管内皮生长因子(VEGF)、神经营养因子-3(NT-3)和神经营养因子-4(NT-4)。In a preferred embodiment, the nerve growth factor mimetic peptide can be any one known in the art, for example, from one or more selected from the group consisting of nerve growth factor (NGF), brain-derived nerve trophic factor (BDNF), vascular endothelial growth factor (VEGF), neurotrophic factor-3 (NT-3) and neurotrophic factor-4 (NT-4).

在一个优选的实施方式中,所述自组装肽序列与神经生长因子模拟肽通过化学键共价连接,摩尔比为(1~3):1,例如,来自选自如下的一种,酰胺键或二硫键。如果选择酰胺键通过固相合成;如果选择二硫键或多肽载体通过表位肽修饰半胱氨酸,固相合成方法,然后将两条肽对接。In a preferred embodiment, the self-assembling peptide sequence and the nerve growth factor mimetic peptide are covalently linked by chemical bonds, and the molar ratio is (1-3): 1, for example, from one selected from the group consisting of amide bonds or disulfide bonds. If the amide bond is selected by solid phase synthesis; if the disulfide bond or the polypeptide carrier is selected by epitope peptide modification of cysteine, solid phase synthesis method, then the two peptides are docked.

本文中提到的巨噬细胞可为来自大鼠/小鼠腹腔或骨髓、或人外周血单个核淋巴细胞中的一种,或者可为采用本领域已知的常规手段分离得到的巨噬细胞。The macrophages mentioned herein can be one of rat/mouse peritoneal cavity or bone marrow, or human peripheral blood mononuclear lymphocytes, or can be macrophages isolated by conventional means known in the art .

在本发明的一个优选的实施方式中,所述细胞的培养可以采用本领域已知的任何的合适的培养基(例如,可参见如下中的记载:http://www.cellbank.org.cn/peiyang.asp;https://www.atcc.org/)进行,例如但不限于含有胎牛血清的RPMI-1640培养基、含有胎牛血清的DMEM培养基、含有胎牛血清的F-12培养基、含有胎牛血清的DMEM/F-12培养基。在进一步优选的实施方式中,所述培养在30℃~40℃、3%~10% CO2的条件下进行。在更进一步优选的实施方式中,所述培养的过程包括:将所述肿瘤细胞在所述培养基中生长至60%~80%的汇合度后,弃去培养液并利用PBS缓冲液进行洗涤,随后向洗涤后的培养物中加入新鲜培养基并继续培养36h以上、例如36~72h、优选40~50h。In a preferred embodiment of the present invention, any suitable medium known in the art can be used for culturing the cells (for example, see the following description: http://www.cellbank.org.cn /peiyang.asp; https://www.atcc.org/), such as but not limited to RPMI-1640 medium containing fetal bovine serum, DMEM medium containing fetal bovine serum, F-12 medium containing fetal bovine serum Medium, DMEM/F-12 medium containing fetal bovine serum. In a further preferred embodiment, the culture is carried out under the conditions of 30°C to 40°C and 3% to 10% CO 2 . In a further preferred embodiment, the culturing process includes: after growing the tumor cells in the culture medium to a confluence of 60%-80%, discarding the culture medium and washing with PBS buffer , then add fresh medium to the washed culture and continue to culture for more than 36h, for example, 36~72h, preferably 40~50h.

在一个优选的实施方式中,采用孔径为0.2~0.45μm的过滤材料对所述细胞培养上清液进行过滤。过滤得到的细胞培养上清液中主要包含:细胞分泌的蛋白质(包括作为影响免疫细胞功能的主要物质的多种细胞因子);非编码RNA(包括小RNA和长链RNA等);DNA等。In a preferred embodiment, the cell culture supernatant is filtered using a filter material with a pore size of 0.2-0.45 μm. The cell culture supernatant obtained by filtration mainly contains: proteins secreted by cells (including various cytokines that are the main substances affecting the function of immune cells); non-coding RNAs (including small RNAs and long-chain RNAs, etc.); DNA, etc.

在一个优选的实施方式中,所述M2巨噬细胞培养上清液的制备方法,其特征在于,所述细胞培养诱导物选自IL-4,优选地,所述细胞培养刺激物为0.1-100 ng/mL,例如10ng/mL的IL-4。加入培养基培养,在本领域已知的任何的合适的培养基(例如,可参见如下中的记载:http://www.cellbank.org.cn/peiyang.asp;https://www.atcc.org/)中进行所述培养,所述培养基例如但不限于含有胎牛血清的RPMI-1640培养基、含有胎牛血清的DMEM培养基、含有胎牛血清的F-12培养基、含有胎牛血清的DMEM/F-12培养基。在进一步优选的实施方式中,所述培养在30℃~40℃、3%~10% CO2的条件下进行。在更进一步优选的实施方式中,所述培养进行36h以上、例如36~72h、优选40~50h。In a preferred embodiment, the method for preparing the M2 macrophage culture supernatant is characterized in that the cell culture inducer is selected from IL-4, preferably, the cell culture stimulus is 0.1- 100 ng/mL, eg 10 ng/mL of IL-4. Add medium for culture, any suitable medium known in the art (for example, see the description in the following: http://www.cellbank.org.cn/peiyang.asp; https://www.atcc .org/), such as but not limited to RPMI-1640 medium containing fetal bovine serum, DMEM medium containing fetal bovine serum, F-12 medium containing fetal bovine serum, DMEM/F-12 medium with fetal bovine serum. In a further preferred embodiment, the culture is carried out under the conditions of 30°C to 40°C and 3% to 10% CO 2 . In a further preferred embodiment, the culturing is performed for more than 36 hours, for example, 36 to 72 hours, preferably 40 to 50 hours.

在一个优选的实施方式中,所述的多肽水凝胶支架,其特征在于,所述支架具有纳米纤维结构。In a preferred embodiment, the polypeptide hydrogel scaffold is characterized in that the scaffold has a nanofiber structure.

在一个优选的实施方式中,所述的多肽水凝胶支架,其特征在于,所述支架具有水凝胶的形态,调节后凝胶的pH为6.9~7.2,浓度为0.5 wt %-4wt%例如1wt%。In a preferred embodiment, the polypeptide hydrogel scaffold is characterized in that the scaffold has the form of a hydrogel, and the pH of the gel after adjustment is 6.9-7.2, and the concentration is 0.5 wt %-4 wt %. For example 1wt%.

在一个优选的实施方式中,每mL所述含有水凝胶的细胞悬液中,具有1×104~1×107个、优选5×104~1×106个、例如1×105个所述神经雪旺细胞。In a preferred embodiment, each mL of the hydrogel-containing cell suspension contains 1×10 4 to 1×10 7 cells, preferably 5×10 4 to 1×10 6 cells, such as 1×10 cells. 5 of the neural Schwann cells.

在一个优选的实施方式中,所述预定形状的支持物可为三维细胞培养支架、细胞培养皿、细胞培养瓶、细胞培养微孔板、双层细胞培养板或本领域已知的任何适用于三位细胞培养的系统,例如6孔细胞培养微孔板、12孔细胞培养微孔板、24孔细胞培养微孔板、96孔细胞培养微孔板、24孔双层细胞培养板或本领域可商购的任何细胞培养微孔板,例如由Thermofisher、FlexCell等提供的商业化的三维细胞培养系统。In a preferred embodiment, the predetermined shape of the support can be a three-dimensional cell culture scaffold, cell culture dish, cell culture flask, cell culture microplate, double-layered cell culture plate or any known in the art suitable for Three-dimensional cell culture system, such as 6-well cell culture microplate, 12-well cell culture microplate, 24-well cell culture microplate, 96-well cell culture microplate, 24-well double-layer cell culture plate, or the like Any cell culture microplate is commercially available, such as the commercial three-dimensional cell culture systems provided by Thermofisher, FlexCell, and the like.

在一个优选的实施方式中,所述3D细胞培养在30℃~40℃、3%~10% CO2的条件下进行2-72h、例如3-72h、6-72h。In a preferred embodiment, the 3D cell culture is carried out at 30°C to 40°C and 3% to 10% CO 2 for 2-72h, such as 3-72h, 6-72h.

在一个实施方式中,本发明涉及上述的多肽水凝胶支架在开发损伤神经修复中的用途。例如,通过将经常规的物理、化学或生物方法处理后的多肽水凝胶支架注射、涂层等方式到神经修复导管内,促进损伤的神经再生。In one embodiment, the present invention relates to the use of the above-mentioned polypeptide hydrogel scaffold in the development of damaged nerve repair. For example, the damaged nerve regeneration can be promoted by injecting or coating the polypeptide hydrogel scaffold treated by conventional physical, chemical or biological methods into the nerve repair catheter.

以下通过实施例对本发明的方案进行进一步说明,但本发明的保护范围并不仅限于此。The solution of the present invention will be further illustrated by the following examples, but the protection scope of the present invention is not limited to this.

实施例Example

如下的实施例仅用于说明的目的,而并非旨在限定本申请的保护范围。除非另有说明,否则如下的实施例中使用的所有试剂、材料和设备均为可商购的,或者可根据本领域公知的现有技术进行配制或获得。除非另有说明,否则如下的实施例中涉及的具体实验手段均为本领域的现有技术(例如,《分子克隆实验指南》(第4版),J. 萨姆布鲁克等编著,贺福初主译,科学出版社,2017年;《医学免疫学》(第7版),曹雪涛主编,人民卫生出版社,2018年)中记载的常规手段。The following examples are for illustrative purposes only, and are not intended to limit the protection scope of the present application. Unless otherwise stated, all reagents, materials and equipment used in the following examples are commercially available, or can be formulated or obtained according to prior art well known in the art. Unless otherwise specified, the specific experimental methods involved in the following examples are all the existing technologies in the field (for example, "Molecular Cloning Experiment Guide" (4th Edition), edited by J. Sambrook et al., translated by He Fuchu , Science Press, 2017; conventional means recorded in "Medical Immunology" (7th edition), edited by Cao Xuetao, People's Medical Publishing House, 2018).

实施例1 自组装肽序列键合神经生长因子模拟肽的制备Example 1 Preparation of self-assembling peptide sequence-bonded nerve growth factor mimetic peptide

将自组装肽序列与神经生长因子模拟肽通过化学键共价连接,摩尔比为1:1,共价连接选自酰胺键,如图1所示,通过固相合成,将两条肽对接(自组装肽序列RADARADARADARADA和脑源性神经营养因子模拟肽GGGIDKRHWNS)。The self-assembled peptide sequence and the nerve growth factor mimetic peptide were covalently linked by chemical bonds, the molar ratio was 1:1, and the covalent linkage was selected from amide bonds. As shown in Figure 1, the two peptides were docked by solid-phase synthesis (self- The assembled peptide sequence RADARADARADARADA and the brain-derived neurotrophic factor mimetic peptide GGGIDKRHWNS).

实施例2 大鼠腹腔巨噬细胞培养Example 2 Rat peritoneal macrophage culture

大鼠腹腔巨噻细胞的提取分离:将2~3月龄(体重约300g)的SD大鼠用脱颈法处死,置于75vol%乙醇中浸泡10 min,然后把大鼠倒置提起,用无菌的注射器往其腹腔内注射10 mL DMEM高糖基础培养基。用手指按摩大鼠腹部2 min后,将大鼠仰卧静置7 min,然后无菌打开大鼠腹腔,用另一无菌注射器抽出腹腔液体大约8 mL,400 g离心10 min,弃去上清液,用6 mL高糖DMEM完全培养基重悬细胞并接种到T25培养瓶中,在37℃、5% CO2细胞培养箱中孵育,4h后换液。贴壁细胞即是提取的大鼠腹腔巨噬细胞。Extraction and isolation of rat peritoneal giant thiamine cells: SD rats aged 2 to 3 months (body weight about 300 g) were killed by de-neck method, soaked in 75 vol% ethanol for 10 min, and then lifted upside down, with no Inject 10 mL of DMEM high-glucose basal medium into the abdominal cavity with a syringe of bacteria. After massaging the abdomen of the rat with fingers for 2 min, the rat was placed in a supine position for 7 min, then the rat abdominal cavity was opened aseptically, about 8 mL of abdominal fluid was drawn out with another sterile syringe, centrifuged at 400 g for 10 min, and the supernatant was discarded. The cells were resuspended in 6 mL high-glucose DMEM complete medium and inoculated into T25 culture flasks, incubated at 37°C in a 5% CO 2 cell incubator, and the medium was changed after 4 h. The adherent cells are the extracted rat peritoneal macrophages.

实施例3 M2巨噬细胞培养上清液的制备Example 3 Preparation of M2 macrophage culture supernatant

分离所得的巨噬细胞并在37℃、5% CO2下用高糖DMEM完全培养基培养3天后,弃去原培养基,更换为10ng/ml IL-4、10%FBS、1%双抗的RMPI 1640培养基,继续培养24h后得到M2型巨噬细胞。培养过程中观察细胞生长状态良好。如图2所示,经共聚焦显微镜拍照后观察细胞伪足明显,形态正常。收集培养获得的M2型巨噬细胞,以CD206抗体作为标记,经流式细胞术检测培养所得的M2型巨噬细胞的纯度。如图3所示,采用含有10 ng/mL的IL-4的高糖DMEM完全培养基刺激3天后,CD206抗体双阳性表达率可到70%以上,M2型巨噬细胞纯度理想。将M2型巨噬细胞培养基换成无血清的高糖培养基培养,24h后收集上清液并用0.22μm过滤器滤去细胞和碎片备用。The obtained macrophages were isolated and cultured in high glucose DMEM complete medium for 3 days at 37°C, 5% CO 2 , the original medium was discarded and replaced with 10ng/ml IL-4, 10% FBS, 1% double antibody The RMPI 1640 medium was cultured for 24 h to obtain M2 macrophages. During the culture, the cells were observed to grow well. As shown in Figure 2, after taking pictures by confocal microscope, it was observed that the pseudopodia of the cells were obvious and the shape was normal. The cultured M2 macrophages were collected and labeled with CD206 antibody, and the purity of the cultured M2 macrophages was detected by flow cytometry. As shown in Figure 3, after stimulation with high glucose DMEM complete medium containing 10 ng/mL of IL-4 for 3 days, the double-positive expression rate of CD206 antibody can reach more than 70%, and the purity of M2 macrophages is ideal. The M2 macrophage medium was replaced with serum-free high-glucose medium for cultivation, and the supernatant was collected after 24 h, and the cells and debris were filtered off with a 0.22 μm filter for use.

实施例4 自组装水凝胶支架的制备和结构表征Example 4 Preparation and structural characterization of self-assembled hydrogel scaffolds

将实施例1所得到的多肽序列溶解在实施例3所得的M2型巨噬细胞上清溶液中,调整浓度,通过多肽自发性自组装形成水凝胶,当组装体的质量浓度在10mg/mL及以上时,如图4-5所示,表现为水凝胶,呈交联的三维网状结构。通过透射电子显微镜,结果表明多肽链段长度和组份对聚合物纳米组装形貌和溶液-凝胶转变温度有较大影响。The polypeptide sequence obtained in Example 1 was dissolved in the M2-type macrophage supernatant solution obtained in Example 3, and the concentration was adjusted to form a hydrogel through spontaneous self-assembly of the polypeptide. When the mass concentration of the assembly was 10 mg/mL and above, as shown in Figure 4-5, it appears as a hydrogel with a cross-linked three-dimensional network structure. Through transmission electron microscopy, the results show that the length and composition of polypeptide segments have a great influence on the morphology and solution-gel transition temperature of polymer nano-assembly.

实施例5 大鼠原代雪旺细胞分离培养方法和3D细胞培养Example 5 Rat primary Schwann cell isolation and culture method and 3D cell culture

取红皮鼠于超净台,用酒精喷,将小鼠尾全身按拭干净,剪去头部。用右手调节小鼠后肢,爪心朝上,左手拇指和食指分别按住小鼠的后肢和尾部。剪去小鼠后肢及尾部上方的皮肤。用弯镊子在后肢凹陷区夹开个口子,延脊柱剪两下,将肉与脊柱分开,剔去上方肉,暴露坐骨神经等要取的组织。取SD红皮细胞1天的坐骨神经置于高糖DMEM完全培养基的培养皿中。轻轻吸掉上清,将坐骨神经取出放入EP管中(5mL)。加胶原酶1mL(20只)消化30min,用眼科剪快速剪碎组织,轻轻吹打混匀放入培养箱(37℃、5% CO2)。30min后加等量1mL0.25%胰酶(Try)轻轻吹打混匀,放培养箱5min。5min后,加至少三倍高糖DMEM完全培养基,终止消化(3-4倍),吹匀,1200rpm离心5min,弃上清。加入新鲜高糖DMEM完全培养基,吹匀,过滤,接种细胞到培养皿中。第二日,在接种16h后换液,用含有阿糖胞苷(1:1000)的高糖DMEM完全培养基培养。隔四日换液,用高DMEM完全培养基培养,直到长满为止。将收集的雪旺细胞与上述的水凝胶支架分别按照1:3的体积比混合均匀,调整其中的细胞浓度为1×105个/mL,于37℃、5% CO2下孵育30分钟,得到包含凝胶的各细胞悬液。Take the red-skinned mouse on the ultra-clean bench, spray it with alcohol, wipe the whole body of the mouse tail, and cut off the head. Adjust the hindlimb of the mouse with the right hand, with the center of the paw facing upward, and press the hindlimb and tail of the mouse with the thumb and index finger of the left hand, respectively. The skin on the hind limbs and the upper tail of the mouse was clipped. Use curved tweezers to open a hole in the depression of the hindlimb, cut twice along the spine, separate the meat from the spine, remove the upper meat, and expose the sciatic nerve and other tissues to be taken. The sciatic nerve with SD erythrocytes for 1 day was placed in a petri dish with high glucose DMEM complete medium. Gently aspirate the supernatant and remove the sciatic nerve into an EP tube (5 mL). Add 1 mL of collagenase (20 pieces) to digest for 30 minutes, quickly cut the tissue with ophthalmic scissors, gently pipette and mix well and put it in an incubator (37°C, 5% CO 2 ). After 30 minutes, add an equal amount of 1 mL of 0.25% trypsin (Try), gently pipetting and mixing, and put it in the incubator for 5 minutes. After 5 min, add at least three times high glucose DMEM complete medium to stop digestion (3-4 times), blow evenly, centrifuge at 1200 rpm for 5 min, and discard the supernatant. Add fresh high-glucose DMEM complete medium, blow well, filter, and seed cells into petri dishes. On the second day, the medium was changed 16 hours after the inoculation, and the cells were cultured with high glucose DMEM complete medium containing cytarabine (1:1000). The medium was changed every four days and cultured with high DMEM complete medium until confluent. The collected Schwann cells were mixed with the above-mentioned hydrogel scaffold according to the volume ratio of 1:3 respectively, and the cell concentration was adjusted to 1×10 5 cells/mL, and incubated at 37°C and 5% CO 2 for 30 minutes. , to obtain each cell suspension containing the gel.

实施例6雪旺细胞分的活性检测Embodiment 6 Activity detection of Schwann cell fraction

CFSE标记后,将雪旺细胞于37℃、5% CO2下在高糖DMEM完全培养基中培养3天后,流式细胞仪检测雪旺细胞的增殖情况。结果在图6中示出。观察细胞呈现为球状,更多的细胞显示出突起,因而能够更好的模拟再生微环境。通流式细胞仪检测,与对照组相比较,水凝胶支架组雪旺细胞的生长速度显著提高。After CFSE labeling, Schwann cells were cultured in high glucose DMEM complete medium for 3 days at 37°C and 5% CO 2 , and the proliferation of Schwann cells was detected by flow cytometry. The results are shown in FIG. 6 . Observe that the cells are spherical, and more cells show protrusions, which can better simulate the regenerative microenvironment. Compared with the control group, the growth rate of Schwann cells in the hydrogel scaffold group was significantly increased by flow cytometry.

Claims (7)

1.一种键合功能多肽,其包含通过共价键键合的自组装肽序列和神经生长因子模拟肽,其中,所述自组装肽序列为RADARADARADARADA、KWKAKAKAKWK、EWEAEAEAE、FEFEFKFKK或QQKFQFQFEQQ,所述神经生长因子模拟肽为GGGIDKRHWNS。1. A bonding functional polypeptide comprising a self-assembling peptide sequence and a nerve growth factor mimetic peptide bonded by a covalent bond, wherein the self-assembling peptide sequence is RADARADARADARADA, KWKAKAKAKWK, EWEAEAEAE, FEFEFKFKK or QQKFQFQFEQQ, and the The nerve growth factor mimetic peptide is GGGIDKRHWNS. 2.如权利要求1所述的键合功能多肽,其特征在于,所述自组装肽序列与神经生长因子模拟肽通过酰胺键或二硫键共价连接。2 . The functional bonding polypeptide of claim 1 , wherein the self-assembling peptide sequence and the nerve growth factor mimetic peptide are covalently linked through an amide bond or a disulfide bond. 3 . 3.如权利要求1或2所述的键合功能多肽,其特征在于,所述自组装肽序列与神经生长因子模拟肽的摩尔比为(1~3):1。The bonding function polypeptide according to claim 1 or 2, wherein the molar ratio of the self-assembling peptide sequence to the nerve growth factor mimetic peptide is (1~3):1. 4.权利要求1-3中任一项所述的键合功能多肽在制备水凝胶支架中的用途,其特征在于,所述键合功能多肽在抗炎M2巨噬细胞的细胞培养上清液中自组装形成所述水凝胶支架。4. The use of the functionally bonded polypeptide according to any one of claims 1-3 in the preparation of a hydrogel scaffold, wherein the functionally bonded polypeptide is in the cell culture supernatant of anti-inflammatory M2 macrophages The hydrogel scaffold is formed by self-assembly in liquid. 5.如权利要求4所述的用途,其特征在于,通过分离并培养来自如下的巨噬细胞,诱导其为“替代性激活”的抗炎M2巨噬细胞:大鼠/小鼠腹腔或骨髓、或人外周血单个核淋巴细胞中的一种。5. The use of claim 4, wherein "alternatively activated" anti-inflammatory M2 macrophages are induced by isolating and culturing macrophages from: rat/mouse peritoneal cavity or bone marrow , or one of human peripheral blood mononuclear lymphocytes. 6.如权利要求5所述的用途,其特征在于,采用10ng/ml的IL-4进行所述的诱导。6. The use of claim 5, wherein the induction is carried out with 10 ng/ml of IL-4. 7.如权利要求4-6中任一项所述的用途,其特征在于,所述支架具有纳米纤维结构。7. The use of any one of claims 4-6, wherein the scaffold has a nanofibrous structure.
CN202210998757.9A 2021-07-27 2021-07-27 Method for preparing hydrogel scaffolds and use of scaffolds obtained thereby Pending CN115160444A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210998757.9A CN115160444A (en) 2021-07-27 2021-07-27 Method for preparing hydrogel scaffolds and use of scaffolds obtained thereby

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210998757.9A CN115160444A (en) 2021-07-27 2021-07-27 Method for preparing hydrogel scaffolds and use of scaffolds obtained thereby
CN202110849059.8A CN113713175B (en) 2021-07-27 2021-07-27 Method for preparing hydrogel scaffolds and uses of scaffolds obtained therefrom

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202110849059.8A Division CN113713175B (en) 2021-07-27 2021-07-27 Method for preparing hydrogel scaffolds and uses of scaffolds obtained therefrom

Publications (1)

Publication Number Publication Date
CN115160444A true CN115160444A (en) 2022-10-11

Family

ID=78674033

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210998757.9A Pending CN115160444A (en) 2021-07-27 2021-07-27 Method for preparing hydrogel scaffolds and use of scaffolds obtained thereby
CN202110849059.8A Active CN113713175B (en) 2021-07-27 2021-07-27 Method for preparing hydrogel scaffolds and uses of scaffolds obtained therefrom

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110849059.8A Active CN113713175B (en) 2021-07-27 2021-07-27 Method for preparing hydrogel scaffolds and uses of scaffolds obtained therefrom

Country Status (1)

Country Link
CN (2) CN115160444A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114230640A (en) * 2021-12-21 2022-03-25 西安交通大学 A kind of amino acid condensate with self-assembly ability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287186A1 (en) * 2003-10-17 2005-12-29 Massachusetts Institute Of Technology Self-assembling peptides for regeneration and repair of neural tissue
JP2016020323A (en) * 2014-07-16 2016-02-04 国立大学法人名古屋大学 Composition for scaffold material for nerve regeneration
CN112516385A (en) * 2020-11-16 2021-03-19 清华大学 Directional fibrin and polypeptide interpenetrating network composite hydrogel for nerve regeneration and preparation method thereof
CN113046316A (en) * 2021-04-07 2021-06-29 中南大学湘雅医院 M2 type bone marrow macrophage exosome, application thereof and spinal cord injury treatment preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526762B1 (en) * 2013-08-09 2016-12-27 William Marsh Rice University Multidomain peptides for promoting angiogenesis
CN104356402B (en) * 2014-10-10 2016-08-31 孙念峰 Functional self-assembled nanometer polypeptide hydrogel
AU2019309769A1 (en) * 2018-07-16 2021-02-04 The Board Trustees Of University Of Illinois Engineered exosomes for medical applications
CN109771694A (en) * 2019-03-20 2019-05-21 江苏瑞思坦生物科技有限公司 The preparation method and application of self assembly polypeptide nano fiber water gel scaffold material

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287186A1 (en) * 2003-10-17 2005-12-29 Massachusetts Institute Of Technology Self-assembling peptides for regeneration and repair of neural tissue
JP2016020323A (en) * 2014-07-16 2016-02-04 国立大学法人名古屋大学 Composition for scaffold material for nerve regeneration
CN112516385A (en) * 2020-11-16 2021-03-19 清华大学 Directional fibrin and polypeptide interpenetrating network composite hydrogel for nerve regeneration and preparation method thereof
CN113046316A (en) * 2021-04-07 2021-06-29 中南大学湘雅医院 M2 type bone marrow macrophage exosome, application thereof and spinal cord injury treatment preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
朱诗国,程晓东主编: "《医学免疫学》", vol. 2020, 30 April 2020, 上海:上海科学技术出版社, pages: 223 - 224 *
鲁长风等: "两种新型功能化自组装多肽水凝胶的制备和体外研究", 《中国医药生物技术》, vol. 13, no. 4, 31 August 2018 (2018-08-31), pages 313 *

Also Published As

Publication number Publication date
CN113713175B (en) 2022-09-16
CN113713175A (en) 2021-11-30

Similar Documents

Publication Publication Date Title
CN102908207B (en) Tissue engineering nerve graft prepared by biological printing technology and preparation method thereof
CN103041450B (en) Cell matrix modified tissue engineering nerve graft for repairing peripheral nerve injury and preparation method thereof
EP1617854B1 (en) Biologically active native biomatrix composition
US10639399B2 (en) Construction of MicroRNA gene-mediated novel tissue engineered nerve and applications thereof in repairing nerve defect
CN107281550A (en) Preparation method of co-crosslinked double-network hydrogel scaffold for promoting cartilage injury repair
JP2010538681A (en) Methods for extracting mesenchymal stem cells from human or animal embryos and their secretions
CN110478528B (en) Preparation method and application of novel tissue repair promoting material
CN105233336B (en) Sericin nerve trachea and the preparation method and application thereof
CN108546674B (en) Pre-stimulated stem cells and preparation method and application thereof
EP2530144A2 (en) Composition comprising cell and biocompatible polymer
CN110812318B (en) Method for preparing optimized fibroblast extract for cosmetic raw material
WO2014117146A1 (en) Growth matrices for stem cell propagation in vitro and in tissue regeneration
CN107254431B (en) Novel tissue engineering skin preparation method
CN119326794B (en) Adipose stem cell composition for wound repair and preparation method and application thereof
CN102861360A (en) Nerve repair promoting material and preparation method and application thereof
CN113713175B (en) Method for preparing hydrogel scaffolds and uses of scaffolds obtained therefrom
CN110804607A (en) Preparation method of high-concentration human mesenchymal stem cell lysate
CN114832149A (en) Wound dressing based on stem cell micro-embedded composite hydrogel and preparation method thereof
CN116514956A (en) Recombinant humanized III type collagen and application thereof
CN113355281B (en) A method for efficiently isolating mouse intramuscular fibro-adipogenic progenitor cells
Bauer et al. Glial‐conditioned medium and attachment to ConA are essential for long‐term culture of cortical neurons
CN108478857B (en) Porous titanium surface collagen coating and preparation method thereof
CN109666642B (en) Method for in vitro separation and purification of oligodendrocyte precursor cells of tree shrew cerebral cortex
CN114480260A (en) Adult lung stem cell exosome and preparation method and application thereof
CN112704768A (en) Chondroitin sulfate modified collagen/polycaprolactone vascular repair stent and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination